Table 2.
Efficacy endpoint analyses
| Efficacy assessment | Treatment group | Hazard ratio (95 % CI) | |||
|---|---|---|---|---|---|
| n | Exemestane | n | Anastrozole | ||
| ERIRC-assessed TTP (FAS), monthsa (95 % CI) | 147 | 13.8 (10.8, 16.5) | 145 | 11.1 (10.8, 16.6) | 1.007 (0.771, 1.317) |
| Investigator-assessed TTP (FAS), monthsa (95 % CI) | 147 | 13.8 (10.0, 16.6) | 145 | 13.7 (10.9, 16.6) | 1.059 (0.816, 1.374) |
| ERIRC-assessed TTP (PPS), monthsa (95 % CI) | 142 | 13.8 (10.8, 16.5) | 138 | 11.1 (9.2, 16.4) | 0.977 (0.746, 1.280) |
| OS (FAS), monthsa (95 % CI) | 147 | NR (49.1, NR) | 145 | 60.1 (4.2, NR) | 1.062 (0.733, 1.539) |
| TTF (FAS), monthsa (95 % CI) | 147 | 13.6 (9.2, 16.6) | 145 | 11.1 (9.4, 14.1) | 1.078 (0.854, 1.362) |
Adapted with permission from Masuda et al. [24]
CI confidence interval, ERIRC expert radiologic images review committee, FAS full analysis set, NR not reached, OS overall survival, PPS per protocol set, TTF time to treatment failure, TTP time to progression
aMedian